Apr. 26, 2018 - "As I have indicated previously, the improved US market access delivered strong growth and Zubsolv® broke its volume record"
Orexo´s pipeline contains projects in different development phases, with a primary therapeutic focus around addiction in all phases, from prevention to treatment. One objective is to increase the pipeline with clinical stage projects. Read more about the development projects below.
Opioid abuse is today the most common cause of death from drug overdose. The problem is greatest in the US, where just over 60,000 Americans died of an overdose in 2016, mainly caused by use of opioids. Orexo’s key market is the US market for the treatment of opioid dependence.
VA Finans "Orexo ser möjligheter med ny Suboxone-generika, första patienterna i EU behandlade med Zubsolv - IR"z… https://t.co/FUde1eD2ke